Amylin deposition in the kidney of patients with diabetic nephropathy

Kidney International

Volumn 72, Issue 2, 2007, Pages 213-218

  Gong, W ^a   Liu, Z H ^a   Zeng, C H ^a   Peng, A ^a   Chen, H P ^a   Zhou, H ^a   Li, L S ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Amylin; Diabetic nephropathy; Renal pathology

Indexed keywords

AMYLIN;

ADULT; ARTICLE; BOWMAN CAPSULE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE SEVERITY; FEMALE; GLOMERULOPATHY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN DEPOSITION; INSULIN RESISTANCE; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ADULT; AMYLOID; AMYLOIDOSIS; CASE-CONTROL STUDIES; CELL PROLIFERATION; DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX; FEMALE; HUMANS; KIDNEY; MALE; MESANGIAL CELLS; MIDDLE AGED; NEPHROSCLEROSIS;

EID: 34447526133     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002305     Document Type: Article

References (32)

1. Johnson KH, O'Brien TD, Jordan K, Westermark P. Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells. Am J Pathol 1989; 135: 245-250.
2. Johnson KH, O'Brien TD, Betsholtz C, Westermark P. Islet amyloid, islet amyloid polypeptide and diabetes mellitus. N Engl J Med 1989; 321: 513-518.
3. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 3629-3643.
4. Sumner Makin O, Serpell LC. Structural characterization of islet amyloid polypeptide fibrils. J Mol Biol 2004; 335: 1279-1288.
5. Hoppener JW, Ahren B, Lips CJ. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 2000; 343: 411-419.
6. Booth DR, Sunde M, Bellotti V et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 1997; 385: 787-793.
7. Hayden MR, Tyagi SC. Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. JOP 2002; 3: 86-108.
8. Leckstrom A, Bjorklund K, Permert J et al. Renal elimination of islet amyloid polypeptide. Biochem Biophys Res Commun 1997; 239: 265-268.
9. Ehrlich JC, Ratner JM. Amyloidosis of the islets of Langerhans, a restudy of islet hyalin in diabetic and nondiabetic individuals. Am J Pathol 1961; 38: 49-59.
10. Clark A, Wells CA, Buley ID et al. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 1988; 9: 151-159.
11. Westermark P, Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 1978; 15: 417-421.
12. Hayden MR, Tyagi SC. 'A' is for amylin and amyloid in Type 2 Diabetes Mellitus. JOP 2001; 2: 124-139.
13. Wendt T, Tanji N, Guo J et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetes nephropathy. J Am Soc Nephrol 2003; 14: 1383-1395.
14. Jaikaran ET, Clark A. Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 2001; 1537: 179-203.
15. 2+ in apoptosis evoked by human amylin in pancreatic islet beta-cells. Biochem J 1999; 343(Part 1): 53-61.
16. Zhang S, Liu J, Saafi EL, Cooper GJ. Induction of apoptosis by human amylin in RINm5F islet beta-cells is associated with enhanced expression of p53 and p21WAF1/CIP1. FEBS Lett 1999; 455: 315-320.
17. Matveyenko AV, Butler PC. Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes 2006; 55: 2106-2114.
18. Lorenzo A, Razzaboni B, Weri GC et al. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994; 368: 756-760.
19. Hiddinga HJ, Eberhardt NL. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. Am J Pathol 1999; 154: 1077-1088.
20. Peng A, Liu Z, Zhou H et al. Amylin induces apoptosis of cultured human mesangial cells. Chin J Nephrol Dial Transplant 2002; 11: 541-546.
21. Konarkowska B, Aitken JF, Kistler J et al. The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells. FEBS J 2006; 273: 3614-3624.
22. Yan SD, Chen X, Fu J et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-691.
23. Hay DL, Christopoulos G, Christopoulos A, Sexton PM. Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans 2004; 32: 865-867.
24. Tanji N, Markowitz GS, Fu C et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1656-1666.
25. Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 2004; 6: 1219-1225.
26. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159-1169.
27. Wookey PJ, Cao Z, van Geenen RC et al. Increased density of renal amylin binding sites in experimental hypertension. Hypertension 1997; 30(Part 1): 455-460.
28. de Koning EJ, Fleming KA, Gray DW, Clark A. High prevalence of pancreatic islet amyloid in patients with end-stage renal failure on dialysis treatment. J Pathol 1995; 175: 253-258.
29. Johnson KH, O'Brien TD, Westermark P. Newly identified pancreatic protein islet amyloid polypeptide: what is its relationship to diabetes? Diabetes 1991; 40: 310-314.
30. Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897.
31. Kapurniotu A, Bernhagen J, Greenfield N et al. Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide. Eur J Biochem 1998; 251: 208-216.
32. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.